Mazdutide
Chinese-developed GLP-1 / glucagon co-agonist (IBI362, licensed from Eli Lilly's LY3305677). Solid Phase 2 data, approved in China for diabetes in 2024, investigational elsewhere.
Choose an option
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
Mazdutide is a dual agonist combining GLP-1's appetite suppression with glucagon's energy-expenditure boost, the same conceptual pairing as Survodutide. Innovent Biologics ran the Phase 2 programme in Chinese populations, which is relevant because Asian body-fat distribution and BMI cutoffs differ from the Western trial benchmarks the rest of this catalogue cites.
Read the full research guideWhy people choose it
- 10 to 15% body-weight reduction at 6 mg over 24 weeks in Phase 2 Chinese trials
- Notable improvement in hepatic fat fraction. Well-suited to users with NAFLD or elevated ALT
- Modest increase in resting energy expenditure from the glucagon arm
- Tolerability comparable to other dual agonists; some users handle it better than Tirzepatide
At a glance
- Experience level
- Advanced
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
Mazdutide
Log in or create a free account to see full details and prices.
Don't have an account? Sign up